SCHEMBL2770848

SCHEMBL2770848

CCCCCCCCCCC(=O)C(=O)N[C@@H](CCC(=O)O)C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 6/20 0.68
PLA2G5 P39877 3/20 0.68
NOD1 Q9Y239 3/20 0.59
PLA2G4A P47712 1/20 0.54
FOLH1 Q04609 1/20 0.51
RIMKLA Q8IXN7 1/20 0.51
NAALAD2 Q9Y3Q0 1/20 0.51
PLA2G2C Q5R387 1/20 0.51
PPARG P37231 6/20 0.48
PPARD Q03181 6/20 0.48
PPARA Q07869 6/20 0.48
HDAC11 Q96DB2 5/20 0.48
TSHR P16473 4/20 0.48
GPR84 Q9NQS5 4/20 0.48
ALDH1A1 P00352 2/20 0.48
TLR2 O60603 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
FABP4 P15090 2/20 0.48
PTPN1 P18031 2/20 0.48
SLC22A6 Q4U2R8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2770844 1.00 PLA2G2A (0.68) PLA2G2APLA2G5NOD1PLA2G4AFOLH1
SCHEMBL2769449 0.90 PLA2G2A (0.72) PLA2G2APLA2G5NOD1PLA2G4A
SCHEMBL2770510 0.90 PLA2G2A (0.72) PLA2G2APLA2G5NOD1PLA2G4APLA2G2C
SCHEMBL2773210 0.88 PLA2G2A (0.58) PLA2G2APLA2G5NOD1PLA2G4APLA2G2C
SCHEMBL2773637 0.88 PLA2G2A (0.58) PLA2G2APLA2G5NOD1PLA2G4APLA2G2C
SCHEMBL2773206 0.88 PLA2G2A (0.58) PLA2G2APLA2G5NOD1PLA2G4APLA2G2C
SCHEMBL1893081 0.88 PLA2G2A (0.68) PLA2G2APLA2G5NOD1PLA2G4A
SCHEMBL5162407 0.88 PLA2G2A (0.68) PLA2G2APLA2G5NOD1PLA2G4A
SCHEMBL5162305 0.88 PLA2G2A (0.68) PLA2G2APLA2G5NOD1PLA2G4A
SCHEMBL28306846 0.88 PLA2G2A (0.68) PLA2G2APLA2G5NOD1PLA2G4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745489-B2 Compositions and methods for inhibition of phospholipase A2 mediated inflammation THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-06-29 US disclosed
EP-1490328-A4 COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION UNIV CALIFORNIA (US) 2007-08-15 EP disclosed
US-20050148549-A1 Compositions and methods for inhibition of phospholipase a2 mediated inflammation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-07-07 US disclosed
EP-1490328-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION The Regents of The University of California (US) 2004-12-29 EP disclosed
WO-2003076389-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148549-A1 Compositions and methods for inhibition of phospholipase a2 mediated inflammation PLA2G4A, PLA2G4B, PLA2G1B PLA2G2A 5/4885PLA2G5 8/4885NOD1 2087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.